This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human MMP-1 Protein, His Tag
catalog :
MM1-H5222
quantity :
50 ug, 1 mg
price :
310 USD, 1800 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
MM1-H5222
product name :
Human MMP-1 Protein, His Tag
quantity :
50 ug, 1 mg
price :
310 USD, 1800 USD
quantity & price :
$310/50ug,$1800/1mg (250ug × 4)
target :
MMP-1
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human MMP-1, His Tag (MM1-H5222) is expressed from human 293 cells (HEK293). It contains AA Phe 20 - Asn 469 (Accession # NP_002412.1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human MMP-1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in 20 mM MES, 150 mM NaCl, pH6.0. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMPs are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. The enzyme encoded by this gene degrades type IV and V collagens. Studies in rhesus monkeys suggest that the enzyme is involved in IL-8-induced mobilization of hematopoietic progenitor cells from bone marrow, and murine studies suggest a role in tumor-associated tissue remodeling. Thrombospondins, intervertebral disc proteins, regulate the effective levels of matrix metalloproteinases (MMPs) 2 and 9, which are key effectors of ECM remodeling.
Matrix metalloproteinase-1 (MMP-1) is also known as interstitial collagenase and fibroblast collagenase. MMP1 is expressed by fibroblasts, keratinocytes, endothelial cells, monocytes and macrophages. MMP-1 breaks down the interstitial collagens, types I, II, and III. MMP1 can degrade a broad range of substrates including types I, II, III, VII, VIII, and X collagens as well as casein, gelatin, myelin basic protein, LSelectin, proTNF, IL1β, IGFBP3, IGFBP5, pro MMP2 and pro MMP9.
References :
(1) Hirose Y, et al., 2008, Am. J. Hum. Genet. 82 (5): 1122–9.
(2) Brinckerhoff CE., et al., 1987, J. Clin. Invest. 79 (2): 542–6.
(3) Huang SF,et al., 2008, Eur. J. Oral Sci. 116 (4): 319–23.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments